Management of restenosis after coronary intervention.

[1]  P. Serruys,et al.  A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. , 1995, The New England journal of medicine.

[2]  V. Fuster,et al.  The Three Processes Leading to Post PTCA Restenosis: Dependence on the Lesion Substrate , 1995, Thrombosis and Haemostasis.

[3]  P. Serruys,et al.  Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions. A quantitative angiographic analysis. , 1995, Circulation.

[4]  H. Suryapranata,et al.  Long-term Effects of Angiopeptin Treatment in Coronary Angioplasty Reduction of Clinical Events but Not Angiographic Restenosis , 1995 .

[5]  P Hall,et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. , 1995, Circulation.

[6]  C. Ayers,et al.  Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. , 1995, Circulation.

[7]  P. De Groote,et al.  Local lesion-related factors and restenosis after coronary angioplasty. Evidence from a quantitative angiographic study in patients with unstable angina undergoing double-vessel angioplasty. , 1995, Circulation.

[8]  M. Leon,et al.  935-32 Differing Mechanisms of Late Arterial Responses to Transcatheter Therapy: A Serial Quantitative Angiographic and Intravascular Ultrasound Study , 1995 .

[9]  M. Leon,et al.  701-2 The Final % Cross-sectional Narrowing (Residual Plaque Burden) is the Strongest Intravascular Ultrasound Predictor of Angiographic Restenosis , 1995 .

[10]  J. A. Painter,et al.  701-5 Endovascular Stents Reduce Restenosis by Eliminating Geometric Arterial Remodeling: A Serial Intravascular Ultrasound Study , 1995 .

[11]  J. Seltzer,et al.  Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product , 1995, Science.

[12]  T. Sanborn,et al.  The history of interventional cardiology: cardiac catheterization, angioplasty, and related interventions. , 1995, American heart journal.

[13]  S. de Servi,et al.  Trapidil (Triazolopyrimidine), a Platelet‐Derived Growth Factor Antagonist, Reduces Restenosis After Percutaneous Transluminal Coronary Angioplasty: Results of the Randomized, Double‐Blind STARC Study , 1994, Circulation.

[14]  W. O’Neill,et al.  Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. , 1994, The New England journal of medicine.

[15]  N. Rothfield.  Book Review Oxford Textbook of Rheumatology Edited by P.J. Maddison, David A. Isenberg, Patricia Woo, and David N. Glass. 1142 pp., illustrated. New York, Oxford University Press, 1993. $210. 0-19-262026-6 , 1994 .

[16]  E J Topol,et al.  Local drug delivery for the prevention of restenosis. Fact, fancy, and future. , 1994, Circulation.

[17]  E. Topol,et al.  Direct thrombin inhibitors in cardiovascular medicine. , 1994, Circulation.

[18]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[19]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[20]  E. Nabel,et al.  Gene therapy for vascular smooth muscle cell proliferation after arterial injury. , 1994, Science.

[21]  R. Califf,et al.  Low Molecular Weight Heparin in Prevention of Restenosis After Angioplasty: Results of Enoxaparin Restenosis (ERA) Trial , 1994, Circulation.

[22]  V. Fuster,et al.  Macrophage Infiltration in Acute Coronary Syndromes: Implications for Plaque Rupture , 1994, Circulation.

[23]  J. Isner,et al.  Focal compensatory enlargement of human arteries in response to progressive atherosclerosis. In vivo documentation using intravascular ultrasound. , 1994, Circulation.

[24]  S. King,et al.  Local delivery of a synthetic antithrombin with a hydrogel-coated angioplasty balloon catheter inhibits platelet-dependent thrombosis. , 1994, Journal of the American College of Cardiology.

[25]  S. Epstein,et al.  The basis of molecular strategies for treating coronary restenosis after angioplasty. , 1994, Journal of the American College of Cardiology.

[26]  J. Isner,et al.  Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. , 1994, The American journal of pathology.

[27]  R. Califf,et al.  Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months , 1994, The Lancet.

[28]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[29]  T. Flotte,et al.  Photodynamic therapy of arteries , 1992, Proceedings of LEOS'94.

[30]  P. Serruys,et al.  Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty A Multicenter Randomized Double‐Blind Placebo‐Controlled Trial , 1993, Circulation.

[31]  T. Ogihara,et al.  Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Finkel,et al.  Do antisense approaches to the problem of restenosis make sense? , 1993, Circulation.

[33]  D. Baim,et al.  Defining coronary restenosis. Newer clinical and angiographic paradigms. , 1993, Circulation.

[34]  I. Palacios,et al.  Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis. , 1993, The American journal of cardiology.

[35]  J. Isner,et al.  Prevention of smooth muscle cell outgrowth from human atherosclerotic plaque by a recombinant cytotoxin specific for the epidermal growth factor receptor. , 1993, The Journal of clinical investigation.

[36]  C M Gibson,et al.  Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. , 1993, Journal of the American College of Cardiology.

[37]  J. Isner,et al.  Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. , 1992, The Journal of clinical investigation.

[38]  Michael Simons,et al.  Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo , 1992, Nature.

[39]  Ward Casscells,et al.  Migration of Smooth Muscle and Endothelial Cells: Critical Events in Restenosis , 1992, Circulation.

[40]  E. Vermaas,et al.  Selection of single-stranded DNA molecules that bind and inhibit human thrombin , 1992, Nature.

[41]  P. Serruys,et al.  Restenosis after coronary angioplasty: the paradox of increased lumen diameter and restenosis. , 1992, Journal of the American College of Cardiology.

[42]  H V Anderson,et al.  Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Reidy,et al.  Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF , 1991, Science.

[44]  M. Savage,et al.  Restenosis after coronary angioplasty: A multilvariate statistical model to relate lesion and procedure variables to restenosis☆ , 1991 .

[45]  B. Waller,et al.  Restenosis 1 to 24 months after clinically successful coronary balloon angioplasty: a necropsy study of 20 patients. , 1991, Journal of the American College of Cardiology.

[46]  V. Fuster,et al.  The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. , 1991, Journal of the American College of Cardiology.

[47]  D. Massel,et al.  Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. , 1990, The Journal of clinical investigation.

[48]  E. Topol,et al.  Factors influencing restenosis after coronary angioplasty. , 1990, The American journal of medicine.

[49]  R. Bar-Shavit,et al.  Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. , 1989, The Journal of clinical investigation.

[50]  H. Baumgartner,et al.  Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. , 1989, Science.

[51]  S. Ellis,et al.  Effect of 18- to 24-hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. , 1989, American heart journal.

[52]  M. Nobuyoshi,et al.  Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. , 1988, Journal of the American College of Cardiology.

[53]  V. Fuster,et al.  Restenosis after arterial angioplasty: a hemorrheologic response to injury. , 1987, The American journal of cardiology.

[54]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[55]  M. Reidy,et al.  Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. , 1983, Laboratory investigation; a journal of technical methods and pathology.